Highlights

• The efficacy of the opioid receptor antagonist naltrexone (2-4 mg daily, peroral) was compared with amitriptyline in people with painful diabetic neuropathy in a randomized crossover trial.
• Low-dose naltrexone showed comparable efficacy but a greater safety and tolerability profile, suggesting its future evaluation in this chronic debilitating condition.

Highlights

• There is a positive relationship between in silico docking and in vitro assays.
• Several of the herbal compounds studied regulate postprandial hyperglycemia.
• Apigenin is a monotherapeutic agent, inhibiting both α-amylase and α-glucosidase.
• Most herbal compounds are not more toxic than acarbose.

Highlights

• This study determined 122 microRNAs in diabetics and 35 microRNAs in prediabetics.
• miR-144-3p could be used as a biomarker of risk in prediabetes and diabetes.
• miR-30d may be associated with insulin resistance and adipogenesis in prediabetics.

Highlights

• We developed a 5-year diabetes risk calculator for Chinese people with CHD and IGT.
• Higher FPG, 2hPG, and HbA1c were major determinants of new-onset diabetes.
• It can inform decision-making when considering primary prevention measures.

Highlights

1. Low-dose colchicine effectively and safely lowered NRCI in T2D patients with microalbuminuria.
2. Low-dose colchicine did not prevent the incidence of overt nephropathy.